Eluminex Biosciences Announces Initial Patient Treatment in Phase 1b LOTUS Study of New Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema (DME).
Pafolacianine received FDA approval on November 29, 2021. This approval has provided surgeons with a novel tool to enhance the visualization of ovarian cancer lesions, thereby improving surgical outcomes.
Maribavir received FDA approval on November 23, 2021. This approval provides a new treatment option for post-transplant patients dealing with refractory CMV infections.
Jul 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.